SAB4200352

Anti-DLC1 (C-terminal) antibody produced in rabbit

~1.5 mg/mL, affinity isolated antibody

• Synonym(s): Anti-ARHGAP7, Anti-Deleted in Liver Cancer 1, Anti-FLJ21120, Anti-HP, Anti-STARD12, Anti-p122-RhoGAP
• UNSPSC Code: 12352203
• NACRES: NA.41

Properties

• biological source: rabbit
• conjugate: unconjugated
• antibody form: affinity isolated antibody
• antibody product type: primary antibodies
• clone: polyclonal
• form: buffered aqueous solution
• mol wt: antigen ~200 kDa
• species reactivity: human
• enhanced validation: recombinant expression; Learn more about Antibody Enhanced Validation
• concentration: ~1.5 mg/mL
• technique(s): western blot: 1-2 μg/mL using lysates of HEK-293T cells overexpressing human DLC1.
• UniProt accession no.: Q96QB1
• shipped in: dry ice
• storage temp.: −20°C
• target post-translational modification: unmodified
• Gene Information: human ... DLC1(10395)

Description

General description

Deleted in liver cancer 1 (DLC1) is a candidate tumor suppressor gene, originally obtained from human hepatocellular carcinoma (HCC). It is mapped to the human chromosome location 8p21-22. The DLC1 gene is majorly expressed in normal human tissues. It contains three major functional domains, sterile α-motif (SAM), Rho guanosine triphosphatase-activating protein (RhoGAP), and steroidogenic acute regulatory-related lipid transfer (START) domains. The N-terminal region of DLC1 localizes to focal adhesions by binding to Src Homology 2 (SH2) domains on tensins.

Specificity

Anti-DLC1(C-terminal) specifically recognizes human DLC1.

Immunogen

synthetic peptide corresponding to a sequence at the C-terminal of human DLC1, conjugated to KLH. The antibody is affinity-purified using the immunizing peptide immobilized on agarose.

Application

Anti-DLC1 (C-terminal) antibody produced in rabbit may be used in immunoblotting.

Biochem/physiol Actions

Deleted in liver cancer 1 (DLC1) interacts with tensin2, a focal adhesion protein, localized at the end of stress fibers, which plays key roles in cytoskeletal organization and cell signaling. Mutations in the focal adhesion targeting (FAT) region of DLC1 reduces its expression and function. The focal adhesion localization of DLC1 is critical for cell motility and morphology. It is also critical for the tumor suppressor activity of DLC1 and under expressed in human hepatocellular carcinoma (HCC) and a variety of cancer types.

Physical form

Solution in 0.01 M phos­phate buffered saline, pH 7.4, containing 15 mM sodium azide.

Storage and Stability

For continuous use, store at 2-8 °C for up to one month. For extended storage, freeze in working aliquots. Repeated freezing and thawing, or storage in “frost-free” freezers,is not recommended. If slight turbidity occurs upon prolonged storage, clarify the solution by centrifugation before use. Working dilutions should be discarded if not used within 12 hours.

Disclaimer

Unless otherwise stated in our catalog, our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Safety Information

• Storage Class Code: 10 - Combustible liquids
• Flash Point(F): Not applicable
• Flash Point(C): Not applicable